If this message does not display properly, please click here to launch your browser.
| The Battle for Market Supremacy in Hepatitis C Virus: Which Drug Will Emerge on Top – Telaprevir or Boceprevir? — A Pharmacor Analyst Call from Decision Resources | ||||
Based on our 2009 Pharmacor Hepatitis C Virus report, Decision Resources is offering an exclusive analyst call entitled The Battle for Market Supremacy in Hepatitis C Virus: Which Drug Will Emerge on Top – Telaprevir or Boceprevir? Because this analyst call will feature report findings, it is ONLY available to purchasers of this report. Please contact us to learn how you can purchase this report and attend the analyst call. At the 60th annual conference of the American Association for the Study of Liver Diseases, promising clinical trial data was presented on Vertex/Johnson & Johnson/Mitsubishi Tanabe’s telaprevir and Schering-Plough’s boceprevir. At the conference, researchers announced that telaprevir-based regimens cured (achieved sustained viral response) more than 80 percent of hepatitis C virus genotype 1-infected treatment-naive patients. Telaprevir demonstrated a similar efficacy when dosed twice daily or three times daily and in combination with peg-IFN-a-2a (Roche’s Pegasys) or peg-IFN-a-2b (Schering-Plough’s PegIntron). According to data presented at the conference from a separate clinical trial, boceprevir-based regimens cured a high proportion of patients who did not become hepatitis C virus RNA negative during four weeks of peg-IFN/ribavirin lead-in phase of the trial. Following the conference, Decision Resources Analyst Alexandra Makarova, M.D., Ph.D., interviewed key opinion leaders to determine their reaction to the news that emerged from the event. Additionally, as a result of the recently-announced improved efficacy and safety profiles of telaprevir and boceprevir, Decision Resources will update its Hepatitis C Virus report to include revised sales forecasts for these drugs through 2018. In this 15-minute analyst call, Dr. Makarova will answer the following questions:
Dr. Makarova will conduct a live Q & A session after the presentation. Registration The Battle for Market Supremacy in Hepatitis C Virus: Which Drug Will Emerge on Top – Telaprevir or Boceprevir? November 19, 2009 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor report and attend the analyst call, please contact us using the information below. In North America — Steve Silvestro at 781-296-2626 or ssilvestro@dresources.com |
|
|||
Terms of Use | Privacy Policy | Contact Us | Careers |
||||
